spacer
home > ebr > winter 2018 > utmost integrity
PUBLICATIONS
European Biopharmaceutical Review

Utmost Integrity

EBR:Why is data integrity so important to the biopharmaceutical industry?

Darren Barrington-Light: The importance of data integrity is nothing new: the accuracy, consistency and completeness of biopharma data has long been of interest to regulatory bodies. However, as international outsourcing becomes increasingly commonplace and supply chains grow in complexity, regulatory authorities are raising their expectations when it comes to the integrity of this data. We have seen from a number of highprofile cases that practices that might once have passed are now inadequate from a regulatory standpoint.

Brian Alliston: At the end of the day, the products we produce must be effective and safe to use. All of us in the biopharma industry have a responsibility to patients to be up to date with the latest data integrity requirements.

Read full article from PDF >>

Rate this article You must be a member of the site to make a vote.  
Average rating:
0
     

There are no comments in regards to this article.

spacer
Darren Barrington-Light is a Senior Manager Product Marketing at Thermo Fisher Scientific, with over 23 years’ experience in the fields of analytical chemistry, chromatography hardware and computer software. After working with Chromeleon CDS for nearly 13 years, he joined the Chromeleon CDS product management team seven years ago, where he has been involved in all aspects of the software’s development.

Brian Alliston is a Data Integrity Expert and CDS Specialist at Sterling Pharma Solutions, where he heads the Chromeleon administration team. He supports quality control and development analysts in the use of Chromeleon CDS and oversees the development of training procedures, SOPs and product-specific report templates.

spacer
Darren Barrington-Light
spacer
spacer
spacer
Brian Alliston
spacer
spacer
Print this page
Send to a friend
Privacy statement
News and Press Releases

BioIVT Acquires Optivia Biotechnology, Adding Transporter Assay Products and Services to its ADME-Tox Portfolio

BioIVT, a leading provider of research models and services for drug development, today announced that it has acquired Santa Clara, CA-based Optivia Biotechnology and its comprehensive portfolio of transporter assays, multi-transporter models, transporter systems biology, and molecular transport research solutions.
More info >>

White Papers

Transforming Temperature Data Management Practices to Reduce Labor Costs and Improve Visibility and Control

Berlinger & Co AG

There are a number of temperature monitoring database options available to the biopharma supply chain professional and choosing the right one can significantly improve workflow which will reduce administrative time. This article will provide insight into practices for improving common processes through enhanced database functionality in the areas of managing data loggers by expiry date, storing and retrieving calibration certificates and acknowledging/documenting common temperature excursion events. Additionally, it describes the unique features and benefits of the Berlinger Smartview® data management system. Smartview® is a “Software as a Service” (SaaS) platform designed to efficiently and accurately manage both workflow and data in a regulatory compliant manner (21 CRF Part 11 & Annex 11). This comprehensive temperature data management system ensures reliability, accuracy, security, accessibility, and visibility to supply chain professionals, enhancing Good Distribution Practices (GDP) of temperature sensitive shipments.
More info >>

 
Industry Events

Partnerships in Clinical Trials Europe 2018

27-29 November 2018, CCIB, Barcelona

Partnerships in Clinical Trials Europe is back – and bigger than ever. Europe’s most complete clinical meeting is bringing together 1000+ of the industry’s leading experts this November for it’s 17th annual gathering, and you’re invited!
More info >>

 

 

©2000-2011 Samedan Ltd.
Add to favourites

Print this page

Send to a friend
Privacy statement